Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Lupus Nephritis May Be As Straightforward As Lupus R&D Gets

Executive Summary

Some drug makers are tackling lupus R&D by focusing on a specific subset of the disease, lupus nephritis, where diagnosis is more clear cut and the clinical endpoints are more straightforward.

You may also be interested in...



Keeping Track: A Duo Of RTOR Approvals, Thumbs Up For First Oral GLP-1 Treatment, And First Ebola Vaccine Nears US Market

The latest drug development news and highlights from our US FDA Performance Tracker.

New AURA Lupus Data Bode Well For Aurinia's Voclosporin In Future Phase III

Long-term data from the AURA-LV study in lupus nephritis show voclosporin is superior to standard of care, raising expectations for future Phase III success.

Leo's Tralokinumab Poised For US Launch In 2021

The dermatology specialist said a BLA for the IL-13 blocker has been accepted by the US FDA for the treatment of atopic dermatitis.

Topics

Related Companies

UsernamePublicRestriction

Register

LL1128165

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel